Large Data Analysis Finds That Intermittent Hormone Therapy Is Equal to Continuous Therapy for Men Who Are Good Initial Responders
The Journal of Clinical Oncology, published an article by Niraula et al. that searched the general literature published through August 2012. They searched MEDLINE, EMBASE, the Cochrane Library, as well as most major conference proceedings. [...]
CHMP Makes A Positive Recommendation on the Use of Xtandi
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted approval of Xtandi in the treatment of men with castrate resistant prostate cancer that has progressed after the use of chemotherapy. [...]
Teleconference – A New PROSPECT for Prostate Cancer Patients this Tuesday at 6 p.m.
Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m. I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at [...]
Bayer Healthcare and Algeta Disappoint & Let Men with Advanced Prostate Cancer Down
The committee to start the early access clinical trials for drugs and treatments for men with advanced prostate cancer has been very hard at work. Based on the leadership and tenacity of Jan Manarite of [...]
Why Prostate Cancer that is Hormone Resistant Still Responds to Hormone Manipulation
I don’t understand why if I have hormone resistant advanced prostate cancer why the new drugs, Zytiga and Xtandi work. These drugs are still hormone therapies, is my prostate cancer hormone resistant? I recently received [...]
On The Horizon- MRI Guided Ultrasound Ablation of Prostate Cancer Tumors
In 1999 there was a new company started, InSightec, when GE Healthcare and Elbit Medical imaging joined their technologies to develop and manufacture non-invasive magnetic resonance (MRI) guided focused ultrasound technologies. The company has been [...]